Al­ny­lam will hire 100 for its new UK of­fice; Puma shares surge as FDA ac­cepts ner­a­tinib NDA

Brex­it Shmex­it. Cam­bridge, MA-based Al­ny­lam is open­ing up a new of­fice in the UK with plans to add 100 staffers to its core team as the biotech starts to steer its RNAi pipeline drugs to Eu­ro­pean ap­provals. The new of­fice is slat­ed for Maid­en­head, “with its strong aca­d­e­m­ic and clin­i­cal re­search sec­tor, as well as its uni­ver­sal health ser­vice and reg­u­la­to­ry bod­ies con­stant­ly striv­ing to be more stream­lined and ef­fi­cient, the UK has a lot to of­fer as a de­vel­op­ment hub for in­no­v­a­tive med­i­cines,” added Bren­dan Mar­tin, Gen­er­al Man­ag­er for UK & Ire­land at Al­ny­lam. “Our in­vest­ment here sig­nals a trust that the UK com­mu­ni­ty will con­tin­ue to treat this mis­sion with the ur­gency and im­por­tance it de­serves.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.